Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Radiotherapy

The importance of local control in pancreatic cancer

The ECOG E4201 study adds another piece of information to a growing body of evidence pointing strongly to the importance of local control and the role of radiotherapy in unresectable pancreatic cancer. Based on this evidence, we believe radiotherapy should be used routinely in this setting.boxed-text

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Loehrer, P. J. Sr et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 29, 4105–4112 (2011).

    Article  CAS  Google Scholar 

  2. Iacobuzio-Donahue, C. A. et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806–1813 (2009).

    Article  CAS  Google Scholar 

  3. Chauffert, B. et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann. Oncol. 19, 1592–1599 (2008).

    Article  CAS  Google Scholar 

  4. Ceha, H. M. et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89, 2222–2229 (2000).

    Article  CAS  Google Scholar 

  5. Shewach, D. S. & Lawrence, T. S. Antimetabolite radiosensitizers. J. Clin. Oncol. 25, 4043–4050 (2007).

    Article  CAS  Google Scholar 

  6. Lawrence T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W. & Shewach, D. S. Radiosensitization of pancreatic cancer cells by 2′, 2′-difluoro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 34, 867–872 (1996).

    Article  CAS  Google Scholar 

  7. McGinn, C. J. et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 19, 4202–4208 (2001).

    Article  CAS  Google Scholar 

  8. Bockbrader, M. & Kim, E. Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert. Rev. Anticancer Ther. 9, 637–647 (2009).

    Article  CAS  Google Scholar 

  9. Ben-Josef, E. et al. Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G.) for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 81 (Suppl. 2), 127–128 (2011).

    Article  Google Scholar 

  10. Murphy, J. D. et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 801–808 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Theodore S. Lawrence.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ben-Josef, E., Lawrence, T. The importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9, 9–10 (2012). https://doi.org/10.1038/nrclinonc.2011.182

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.182

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing